Updated:
Oy Medix Biochemica
Raimo Kivinen's family office reinvests the proceeds from the 2021 sale of Medix Biochemica Oy into European diagnostics and life sciences ventures.
Oy Medix Biochemica
Oy Medix Biochemica Ab is the Espoo-based family office of Raimo Kivinen, established after the landmark sale of Medix Biochemica Oy to private equity firm Nordic Capital in 2021. The parent company, founded in 1985, grew over four decades into a global supplier of antibodies, antigens, and other critical raw materials for the in-vitro diagnostics industry, operating production sites across Finland, France, and the United States. The exit created significant liquidity that the family office now stewards. The office deploys capital primarily through direct equity investments in early-stage and growth-stage European life sciences companies, with a strong emphasis on diagnostics platforms, medical devices, and enabling biotechnologies. Kivinen has shown a preference for Finnish and Nordic healthcare innovators, leveraging decades of operational expertise to provide hands-on guidance to portfolio companies. Public record indicates the office participates in both seed rounds and larger consortium-led growth financings, occasionally co-investing alongside Nordic venture funds and other regional family offices. Team composition remains private, though the office is understood to operate from the Helsinki metropolitan area with Kivinen maintaining active involvement in investment decisions. A related philanthropic structure has not been publicly detailed. The office's posture remains deliberately low-profile, consistent with Nordic family-office norms — it maintains no public website dedicated to its investment activities, relying instead on its founder's network for proprietary deal flow. Structurally, Oy Medix Biochemica Ab blurs the line between holding company and family office: the corporate entity retains the legacy Medix Biochemica name, suggesting it may hold residual interests or royalty streams from the diagnostics business in addition to its venture portfolio. This hybrid architecture is common among European entrepreneurial families who prefer to reinvest within a single corporate vehicle rather than create separately branded family-office entities.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Finland
City
Espoo
Corporate office
Espoo, Finland
Principals
Raimo Kivinen
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Oy Medix Biochemica Ab?
Founder Raimo Kivinen maintains direct oversight of investment decisions. Kivinen built Medix Biochemica Oy from 1985 onward and retains deep technical and commercial knowledge of the diagnostics supply chain. His network within the Nordic life sciences community is the primary origination channel for the office's deal flow.
How is Oy Medix Biochemica Ab related to the diagnostics company Medix Biochemica?
The family office Oy Medix Biochemica Ab is the investment vehicle of founder Raimo Kivinen, established following the 2021 sale of the operating company Medix Biochemica Oy to Nordic Capital. The office retains the legacy corporate name but does not appear to operate the original diagnostics manufacturing business. It is possible the entity holds minority rollover equity or contingent payments from the transaction, though this is not publicly confirmed.
What investment stages does Oy Medix Biochemica Ab typically target?
The office invests from seed through growth stages, concentrating on European life sciences. Kivinen's track record suggests comfort leading early rounds where his operational expertise directly benefits founders, and participating in later consortium rounds alongside Nordic venture capital firms. The office does not appear to operate a fund-of-funds program.
Does Oy Medix Biochemica Ab accept third-party capital or operate as a multi-family office?
No. The entity functions as a single family office for Raimo Kivinen. There is no public indication it manages assets for other families or external limited partners, consistent with the typical Nordic single-family-office structure where wealth remains closely held within one corporate vehicle.
Which geographies does Oy Medix Biochemica Ab focus on?
The primary focus is Finland and the broader Nordic region, with additional exposure to Western European life sciences hubs. Kivinen's former operating company maintained production sites in Finland, France, and the United States, suggesting some transatlantic familiarity, but the family office's known commitments cluster in Northern Europe.
Does Oy Medix Biochemica Ab participate in fund commitments or only direct deals?
The office is primarily a direct investor. While it occasionally co-invests alongside venture funds, there is no public record of significant limited-partner commitments to third-party funds. Kivinen's model relies on deploying operational expertise alongside his own capital rather than allocating to external managers.
Where does the underlying wealth come from?
The wealth derives from the 2021 sale of Medix Biochemica Oy, a Finnish diagnostics raw-materials manufacturer founded by Raimo Kivinen in 1985, to Nordic Capital. The company grew into a global supplier of antibodies, antigens, and quality-control products used in clinical testing, generating the liquidity base the family office now invests.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: